Galapagos

Galapagos, following Sanofi’s playbook, offloads French R&D site to drug discovery CRO
Galapagos, following Sanofi’s playbook, offloads French R&D site to drug discovery CRO
Fierce Biotech
Galapagos
Sanofi
R&D
CROs
NovAliX
Flag link:
Galapagos' Jyseleca flops phase 3 Crohn's study, dealing another blow to troubled JAK inhibitor
Galapagos' Jyseleca flops phase 3 Crohn's study, dealing another blow to troubled JAK inhibitor
Fierce Pharma
Galapagos
FDA
filgotinib
Crohn's Disease
clinical trials
Jyseleca
Flag link:
Galapagos lays off 200 staff, drops kidney and fibrosis programs in renewed CAR-T push
Galapagos lays off 200 staff, drops kidney and fibrosis programs in renewed CAR-T push
Fierce Biotech
Galapagos
layoffs
CAR-T
Flag link:
Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Clinical Trials Arena
clinical trials
psoriasis
psoriatic arthritis
Lipidor
AKP-02
Amgen
ABP-654
Hengyi
HPP-737
Galapagos
Jyseleca
Flag link:
Galapagos cleans closet of another 4 programs to make room for CAR-T ambitions
Galapagos cleans closet of another 4 programs to make room for CAR-T ambitions
Fierce Biotech
Galapagos
CAR-T
Flag link:
In first M&A strike, Paul Stoffels lays out 5-year plan to turn Galapagos around
In first M&A strike, Paul Stoffels lays out 5-year plan to turn Galapagos around
Fierce Biotech
Galapagos
Pharma CEOs
Paul Stoffels
M&A
CAR-T
AboundBio
CellPoint
Flag link:
Galapagos to enter cell therapy space with acquisition of CellPoint and AboundBio
Galapagos to enter cell therapy space with acquisition of CellPoint and AboundBio
Seeking Alpha
Galapagos
cell therapy
CellPoint
AboundBio
CAR-T
Flag link:
Galapagos’ Jyseleca gets UK marketing authorization for ulcerative colitis
Galapagos’ Jyseleca gets UK marketing authorization for ulcerative colitis
Pharmaceutical Business Review
Galapagos
UK
ulcerative colitiis
Jyseleca
filgotinib
Flag link:
Galapagos CEO to retire, though successor yet to be announced
Galapagos CEO to retire, though successor yet to be announced
BioPharma Dive
Galapagos
Pharma CEOs
Flag link:
Galapagos avoids 'complete whiff' as key anti-inflammatory drug fails to beat placebo in midphase trials
Galapagos avoids 'complete whiff' as key anti-inflammatory drug fails to beat placebo in midphase trials
Fierce Biotech
Galapagos
clinical trials
rheumatoid arthritis
ulcerative colitis
psoriasis
filgotinib
Flag link:
Galapagos Touts Positive Post-Hoc Data, but Likely Won’t Gun for US Approval
Galapagos Touts Positive Post-Hoc Data, but Likely Won’t Gun for US Approval
BioSpace
Galapagos
ulcerative colitis
filgotinib
Flag link:
Galapagos reports long-awaited safety data for inflammation drug
Galapagos reports long-awaited safety data for inflammation drug
BioPharma Dive
Galapagos
inflammation
clinical trials
filgotinib
Flag link:
Gilead's $5B Galapagos black hole widens as pair toss out phase 3 asset after flop
Gilead's $5B Galapagos black hole widens as pair toss out phase 3 asset after flop
Fierce Biotech
Gilead Sciences
Galapagos
IPF
ziritaxestat
Flag link:
Gilead downsizes multibillion-dollar deal once at center of CEO's rebuild
Gilead downsizes multibillion-dollar deal once at center of CEO's rebuild
Bizjournals
Gilead Sciences
Galapagos
clinical trials
filgotinib
rheumatoid arthritis
inflammatory bowel disease
Flag link:
Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline
Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline
EP Vantage
Galapagos
GLPG1205
idiopathic pulmonary fibrosis
clinical trials
Flag link:
Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal
Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal
Fierce Biotech
Galapagos
Servier
GLPG1972
osteoarthritis of the knee
clinical trials
Flag link:
Gilead and Galapagos's filgotinib shows sustained efficacy in ulcerative colitis study
Gilead and Galapagos's filgotinib shows sustained efficacy in ulcerative colitis study
Seeking Alpha
filgotinib
Gilead Sciences
Galapagos
clinical trials
ulcerative colitis
Flag link:
Go or no go? Valuable drugs set for FDA decisions
Go or no go? Valuable drugs set for FDA decisions
EP Vantage
FDA
drug approvals
Novartis
inclisiran
Biomarin
valrox
Roche
risdiplam
GSK
belantamab mafodotin
Gilead Sciences
Galapagos
filgotinib
Flag link:
3 Biotech Stocks With Big Incoming Catalysts
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
FDA
GW Pharma
Epidiolex
filgotinib
Galapagos
Biomarin
valoctocogene roxaparvovec
Flag link:
Go or no go? Pandemic looms over FDA timelines
Go or no go? Pandemic looms over FDA timelines
EP Vantage
Jazz Pharma
Gilead Sciences
Galapagos
GSK
FDA
pandemic
COVID-19
Flag link:

Pages